Paper Details

  1. Home
  2. Paper Details

"Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".

Author: KhanAbdul Moiz, MujeebAzka, NasserNathalie, ShahnoorSyeda, ShaukatAyesha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The study highlighted the FDA approval of Veozah (Fezolinetant) as a nonhormonal treatment for moderate to severe vasomotor symptoms (VMS) in menopause. Fezolinetant, an NK3 receptor antagonist, targets the disrupted thermoregulation underlying VMS and offers relief from hot flashes and night sweats.
Paper Details　
Original Abstract of the Article :
Vasomotor symptoms (VMS) are a common and distressing experience during menopause, affecting a significant portion of women. Hormone therapy (HT) has been the traditional treatment, but its limitations and potential risks have led to the search foar non-hormonal alternatives. Recently, the FDA appro...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551868/

データ提供：米国国立医学図書館（NLM）

Veozah (Fezolinetant): A Non-Hormonal Solution for Vasomotor Symptoms

Vasomotor symptoms (VMS), common and often distressing during menopause, have traditionally been treated with hormone therapy (HT). However, the search for non-hormonal alternatives has led to the development of Veozah (Fezolinetant), a promising new treatment. Veozah, an NK3 receptor antagonist, targets the disrupted thermoregulation that underlies VMS. Clinical trials have demonstrated its efficacy and safety, offering relief from hot flashes and night sweats.

A Non-Hormonal Beacon in the Desert of Menopause

Veozah represents a significant advancement in the management of VMS, offering women a non-hormonal option that can improve their quality of life. This breakthrough addresses a critical need for a safe and effective treatment that avoids the potential risks associated with HT.

Navigating the Desert of Menopause

The desert of menopause can be a challenging landscape for women, characterized by fluctuating temperatures and unpredictable terrain. Veozah, like a trusty camel, offers reliable support, helping women navigate the discomfort of VMS and reach a more comfortable destination.

Dr.Camel's Conclusion

The FDA approval of Veozah is a testament to the progress made in understanding and managing VMS. This non-hormonal treatment provides women with a valuable option for alleviating the discomfort and disruption caused by hot flashes and night sweats, enhancing their well-being during this natural transition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-31
Further Info :

Pubmed ID

37808928

DOI: Digital Object Identifier

PMC10551868

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.